iTeos Therapeutics Announces Strategic Wind Down Plan

iTeos Therapeutics ( (ITOS) ) has issued an update.

On May 28, 2025, iTeos Therapeutics announced its plan to wind down its clinical and operational activities as part of a strategic review to maximize shareholder value. This decision follows the termination of its belrestotug development program and collaboration with GlaxoSmithKline, leading to expected charges related to severance, contract terminations, and winding down costs. The company will focus on leveraging its cash balance and exploring potential asset sales, including EOS-984, EOS-215, and a preclinical obesity program targeting ENT1, to deliver near-term value to shareholders.

The most recent analyst rating on (ITOS) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on iTeos Therapeutics stock, see the ITOS Stock Forecast page.

Spark’s Take on ITOS Stock

According to Spark, TipRanks’ AI Analyst, ITOS is a Neutral.

iTeos Therapeutics is facing significant financial challenges, with declining profitability and cash flow issues being the most pressing concerns. The recent termination of the collaboration with GSK further compounds these challenges. While technical analysis shows potential for short-term upward momentum, the poor valuation and overall negative sentiment associated with recent corporate events weigh heavily on the stock. Investors are advised to be cautious and closely monitor the company’s efforts to improve its financial health and strategic direction.

To see Spark’s full report on ITOS stock, click here.

More about iTeos Therapeutics

iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of immuno-oncology therapeutics. The company leverages its expertise in tumor immunology and immunosuppressive pathways to create innovative product candidates aimed at restoring the immune response against cancer. iTeos Therapeutics is based in Watertown, Massachusetts, with a research center in Gosselies, Belgium.

Average Trading Volume: 892,958

Technical Sentiment Signal: Sell

Current Market Cap: $326.5M

Find detailed analytics on ITOS stock on TipRanks’ Stock Analysis page.